Paulo M. Hoff
机构: Professor de Oncologia, Faculdade de Medicina, Universidade de Sao Paulo
每年引用次数
引用次数
引用: 30,097
H-指数: 75
I10-指数 : 242
出版物: 810
High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis.
B. George , J. Estrella , K. K. Machado , R. Ferrarotto
Journal of Clinical Oncology 29
2011
Health-related quality-of-life (HRQoL) reporting by randomized cancer trials (RCT): Pitfalls for interpretation.
L. Testa , C. C. Barbosa , A. C. Chaves , P. M. Hoff
Journal of Clinical Oncology 29 6102 -6102
2011
Cancer patient (CP), health care professional (HCP), and layperson priorities between survival time (ST) and quality of life (QOL).
E. D. Saad , G. N. Marta , L. G. Del Nero , G. N. Marta
Journal of Clinical Oncology 29
1
2011
Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings.
A. I. Leal , W. F. Barra , D. F. Saragiotto , E. D. Saad
Journal of Clinical Oncology 28 6116 -6116
2
2010
The feasibility and real-life effectiveness of the combination of chemotherapy (CT) and bevacizumab (Bev) in the treatment of high-grade gliomas (HGG) in a private community oncology center.
A. Calabrich , F. C. Azevedo , E. D. Saad , F. C. Maluf
Journal of Clinical Oncology 28
1
2010
Nonepithelial ovarian cancer: Outcomes after aggressive treatment with surgery and platinum-based chemotherapy.
K. K. Machado , D. R. Nebuloni , M. D. Estevez-Diz , G. Castro
Journal of Clinical Oncology 28 ( 15)
1
2010
Prevalence of germline BRCA1 and BRCA2 deleterious and of unknown clinical significance (UCS) mutations in positive hormone receptor female breast cancer patients.
M. D. Estevez-Diz , S. Maistro , K. A. Escobar , F. S. Pasini
Journal of Clinical Oncology 28 ( 15_suppl) e12006 -e12006
2010
Oxaliplatin-related neurotoxicity: is chelation the solution?
Paulo M Hoff
Nature Reviews Clinical Oncology 1 ( 2) 78 -79
2
2004
Does the addition of oxaliplatin increase the risk of capecitabine-induced cardiotoxicity?
Phuong KH Morrow , Paulo M Hoff
Nature Reviews Clinical Oncology 3 ( 2) 76 -77
2
2006
HBPD: Table of Contents Vol. 7, No. 6, 2008
Gwen Lomberk , Martín E Fernández-Zapico , Hanna Pelli , Riitta Lappalainen-Lehto
Pancreatology 9 ( 3) 317 -319
2009
33rd Annual Meeting of the Pancreatic Society of Great Britain and Ireland. October 30–31, 2008, Derby, UK
Gwen Lomberk , Martín E Fernández-Zapico , Hanna Pelli , Riitta Lappalainen-Lehto
Pancreatology 9 ( 3) 302 -314
2009
IAP Society News
Gwen Lomberk , Martín E Fernández-Zapico , Hanna Pelli , Riitta Lappalainen-Lehto
Pancreatology 9 ( 4) 545 -545
2009
HBPD: Table of Contents Vol. 8, No. 1, 2009
Gwen Lomberk , Martín E Fernández-Zapico , Hanna Pelli , Riitta Lappalainen-Lehto
Pancreatology 9 ( 3) 320 -322
2009
EPC Society News
Gwen Lomberk , Martín E Fernández-Zapico , Hanna Pelli , Riitta Lappalainen-Lehto
Pancreatology 9 ( 4) 546 -546
2009
EPC Society News
Gwen Lomberk , Michael J Levy , Koji Tsuruta , Shinichiro Horiguchi
Pancreatology 7 ( 5-6) 551 -551
2007
Deputy Editors
Edward Chu , Ghassan Abou-Alfa , Chloe Atreya , Nathan Bahary
2019
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
James C Yao , Alexandria Phan , Paulo M Hoff , Helen X Chen
Journal of Clinical Oncology 26 ( 8) 1316 -1323
347
2008
Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors.
Peter Kozuch , Paulo M Hoff , Kenneth Hess , Jennifer Adams
Cancer 91 ( 4) 815 -821
5
2001
Managing risks of oncology clinical trials during COVID-19 pandemic
Roberto J Arai , Camila MV Moniz , André TC Chen , Milena P Mak
Contemporary Clinical Trials Communications
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy
Paul Ruff , David R Ferry , Radek Lakomỳ , Jana Prausová
European Journal of Cancer 51 ( 1) 18 -26
16
2015